Do you have any questions?
Don't hesitate to contact us. We are happy to answer your questions.
Meet us at ASH2022
Meet our medical team to find out more about our clinical program and CAR T therapies on December 10-13, 2022 in New Orleans, Louisiana, USA
Meet us at ASH2022
Meet our medical team to find out more about our clinical program and CAR T therapies on December 10-13, 2022 in New Orleans, Louisiana, USA
We are looking forward to your visit
We are excited to be present at #ASH22 on December 10-13, 2022 in New Orleans and look forward to welcoming you to our booth where you will be able to speak to our medical team about our clinical program and open trials. Check out this web page to see what we can discuss with you in New Orleans.
#ASH 2022 will take place in the Ernest N. Morial Convention Center in New Orleans, Louisiana. You will find us at the
Miltenyi Biotec Booth 3355.
Exhibit opening hours:
Saturday 11:00 a.m.–5:00 p.m.
Sunday 10:00 a.m.–5:00 p.m.
Monday 10:00 a.m.–2:00 p.m.
Latest resources and news about Miltenyi Biomedicine presented at #ASH22
DALY 2-EU trial –
now recruiting
Visit official trial page
Downloads and preview links
Take a view at our recent posters and presentations
Bispecific anti-CD20/19 CAR-T – zamtocabtagene autoleucel for relapsed/refractory DLCBL – interim analysis results of DALY-II-USA study
EHA2023 Hybrid Congress | poster information
Interim analysis of a Phase II study of administered fresh bispecific anti-CD20/anti-CD19 CAR T cell therapy zamtocabtagene autoleucel (zamto-cel) for relapsed/refractory (R/R) DLBCL (DALY II USA, NCT04792489)
Tandem Meetings of ASTCT and CIBMTR 2023 I presentation slides
PHASE I TRIAL OF MB-CART2019.1 IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
EHA 2022 | poster download
Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial
ASH 2022 | presentation abstract
Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
ASH 2022 | presentation abstract
Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany
ASH 2022 | presentation abstract
